

Marta Coscia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8197658/publications.pdf>

Version: 2024-02-01

110
papers

3,547
citations

147801

31
h-index

149698

56
g-index

112
all docs

112
docs citations

112
times ranked

5378
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	5
2	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2076.	2.4	6
3	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	3.7	3
4	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	5.2	2
5	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	7.2	17
6	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021, 35, 737-746.	7.2	61
7	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	2.2	5
8	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. <i>Journal of Personalized Medicine</i> , 2021, 11, 249.	2.5	6
9	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	1.7	8
10	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2021, 137, 2267-2271.	1.4	10
11	Targeting HIF-1 β Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. <i>Cancers</i> , 2021, 13, 2883.	3.7	12
12	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	1.4	30
13	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	3.7	16
14	Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3856.	3.7	12
15	CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 4239.	3.7	1
16	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. <i>Blood Advances</i> , 2021, .	5.2	14
17	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
18	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1

#	ARTICLE	IF	CITATIONS
19	HIF-1 α is over-expressed in leukemic cells from <i>TP53</i> -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	3.5	39
20	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. <i>Leukemia</i> , 2020, 34, 462-477.	7.2	24
21	Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2197-2199.	1.8	5
22	Editorial: CAR T-Cell Therapies in Hematologic Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 588134.	2.8	2
23	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	2.8	12
24	Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 594556.	4.8	39
25	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	4.8	45
26	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
27	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. <i>Cancers</i> , 2020, 12, 1773.	3.7	4
28	Frontline treatment with the combination obinutuzumab \pm chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12
29	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. <i>Cancers</i> , 2020, 12, 282.	3.7	22
30	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020, 105, 2671-2674.	3.5	1
31	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
32	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
33	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	1.4	0
34	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
35	Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study. <i>Blood</i> , 2020, 136, 21-22.	1.4	4
36	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020, 136, 54-55.	1.4	2
38	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. <i>Blood</i> , 2020, 136, 25-26.	1.4	3
39	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	1.7	13
40	Venetoclax in CLL patients who progress after Bâ€cell Receptor inhibitor treatment: a retrospective multiâ€centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	2.5	14
41	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-NaÃve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	3.7	16
42	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278-S279.	0.4	0
43	CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. <i>Leukemia Research</i> , 2019, 83, 106169.	0.8	8
44	Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. <i>Leukemia</i> , 2019, 33, 1030-1051.	7.2	4
45	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1284-1315.	3.0	12
46	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. <i>Blood</i> , 2019, 134, 5485-5485.	1.4	1
47	Front-Line Treatment with Obinutuzumab Â± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. <i>Blood</i> , 2019, 134, 1766-1766.	1.4	0
48	External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. <i>Blood</i> , 2019, 134, 4308-4308.	1.4	0
49	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	3.5	30
50	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	7.2	8
51	CD200 included in a 4â€marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 543-546.	1.7	21
52	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term followâ€up. <i>British Journal of Haematology</i> , 2018, 181, 693-695.	2.5	1
53	External validation of the accuracy of â€CLLflow scoreâ€™. <i>Journal of Investigative Medicine</i> , 2018, 66, e6-e6.	1.6	4
54	LDH as Predictive Parameter in Treatment-NaÃve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Regulation of HIF-1 β in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.4	0
56	Predictive value of the Δ CD19/CD20 in CLL patients receiving chemoimmunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706.	2.2	8
57	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	1.4	6
58	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	1.4	2
59	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7531-7531.	1.6	0
60	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 411-425.	1.8	9
61	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	3.5	9
62	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2017, 99, 306-314.	2.2	12
63	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	2.2	29
64	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	1.8	13
65	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. <i>Blood Advances</i> , 2016, 1, 47-61.	5.2	48
66	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	2.8	22
67	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 2429-2431.	1.3	10
68	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 111-123.	1.4	151
69	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
70	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504.	3.5	22
71	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , 2015, 29, 1360-1365.	7.2	57
72	Anergic bone marrow α 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. <i>Oncimmunology</i> , 2015, 4, e1047580.	4.6	58

#	ARTICLE	IF	CITATIONS
73	The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. <i>Leukemia</i> , 2015, 29, 356-368.	7.2	33
74	SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. <i>Journal of Clinical Investigation</i> , 2015, 126, 181-194.	8.2	44
75	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015, 6, 29833-29846.	1.8	33
76	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , 2015, 126, 2925-2925.	1.4	0
77	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 841-847.	1.3	17
78	Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 1060-1070.	7.2	105
79	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. <i>Haematologica</i> , 2014, 99, 888-896.	3.5	43
80	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2014, 99, e159-e161.	3.5	4
81	The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. <i>Haematologica</i> , 2014, 99, 1605-1610.	3.5	27
82	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. <i>Haematologica</i> , 2013, 98, 953-963.	3.5	195
83	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2013, 122, 4177-4177.	1.4	2
84	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e60975.	2.5	49
85	Dysfunctional V β 9V α 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	1.4	51
86	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 3881-3881.	1.4	0
87	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012, 120, 3878-3878.	1.4	0
88	The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1778-1778.	1.4	0
89	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	7.2	61
90	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. <i>Blood</i> , 2011, 118, 6141-6152.	1.4	122

#	ARTICLE	IF	CITATIONS
91	VÎ³9VÎ² T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cellular and Molecular Life Sciences, 2011, 68, 2419-2432.	5.4	35
92	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between VÎ³9VÎ² T Cells, Î±Î² CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. Journal of Immunology, 2011, 187, 1578-1590.	0.8	77
93	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. Blood, 2011, 118, 2845-2845.	1.4	0
94	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 2010, 14, 2803-2815.	3.6	228
95	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. Experimental Hematology, 2009, 37, 728-738.	0.4	10
96	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. Blood, 2009, 114, 2333-2333.	1.4	12
97	Murine Î²-defensin 2 promotes TLR-4/MyD88-mediated and NF-Î²B-dependent atypical death of APCs via activation of TNFR2. Journal of Leukocyte Biology, 2008, 83, 998-1008.	3.3	61
98	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111, 2765-2775.	1.4	239
99	Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma. Clinical Cancer Research, 2007, 13, 5348-5354.	7.0	26
100	Effector Î³Î² T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia, 2005, 19, 664-670.	7.2	119
101	Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T?cells. European Journal of Immunology, 2005, 35, 1155-1163.	2.9	45
102	Therapeutic idiotype vaccines in B lymphoproliferative diseases. Expert Opinion on Biological Therapy, 2004, 4, 959-963.	3.1	11
103	Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. Journal of Leukocyte Biology, 2004, 76, 77-85.	3.3	28
104	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 2004, 18, 139-145.	7.2	63
105	Cancer immunotherapy with chemoattractant peptides. Seminars in Cancer Biology, 2004, 14, 209-218.	9.6	27
106	Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood, 2004, 104, 1961-1969.	1.4	55
107	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. British Journal of Haematology, 2001, 113, 1051-1059.	2.5	48
108	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. British Journal of Haematology, 2000, 109, 46-53.	2.5	16

#	ARTICLE	IF	CITATIONS
109	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	127
110	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	2